Behandling av myelom när högdoskemoterapi inte är möjlig

Bortezomib consolidation after autologous stem cell

2012 (English) In: European Journal of Haematology, ISSN 0902-4441, E-ISSN 1600-0609, Vol 2013 (English) In: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 121, no 23, p. 4647-4654 Article in journal (Refereed) Published Abstract [en] The Nordic Myeloma Study Group conducted an open randomized trial to compare bortezomib as consolidation therapy given after high-dose therapy and autologous stem cell transplantation (ASCT) with no consolidation in bortezomib-naive patients with newly DMSG’s cooperation with Nordic Myeloma Study Group (NMSG) DMSG has a close working relationship with the Nordic organization, NMSG, which in the past 20 years has executed clinical studies with extensive national participation from departments in Norway, Sweden, Island, and Denmark. Niels Abildgaard is currently serving as chair for NMSG. This includes being the national coordinator of 30 clinical myeloma trials, and in addition being the principal investigator of 3 large myeloma studies.

Keldsen N(1), Bjerrum OW, Dahl IM, Drivsholm A, Ellegaard J, Gadeberg O, Gimsing P, Grønvold T, Hansen MM, Hippe E, et al. Nordic Myeloma Study Group, the first 15 years: Scientific collaboration and improvement of patient care. / Hippe, E; Westin, Jan; Wisloff, F. I: European Journal of The Nordic MDS Group is a scientific organisation aiming to improve treatment for patients with myelodysplastic syndromes, and to facilitate research about disease biology. The group was founded in 1984 and encompass since 2001 all Nordic countries. The aim of the NMSG patient-reported outcomes and quality of life (PRO/QOL) Working group is to investigate QOL aspects of patients with multiple myeloma. Methods.

Klinisk prövning på Multiple Myeloma: thalidomide, placebo

Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. The Nordic Myeloma Study Group conducted an open randomized trial to compare bortezomib as consolidation therapy given after high-dose therapy and autologous stem cell transplantation (ASCT) with no consolidation in bortezomib-naive patients with newly diagnosed multiple myeloma.

Welcome to Unijos LMS

Here you can find the study protocols of all ongoing NMSG trials. Nordic Myeloma Study Group (NMSG) was established in 1987 by Nordic haematologists with a special interest in clinical myeloma research. NMSG is an independent Nordic organization of research active MDs and Norwegian, Swedish, Icelandic, Finnish, Estonian, Lithuanian, and Danish clinics / hospitals who conduct clinical myeloma research.

When a randomized trial (NMSG 4/90) comparing treatment with melphalan/prednisone to melphalan/ prednisone + interferon alpha-2b in newly diagnosed multiple myeloma was initiated in 1990, a quality-of-life assessment was integrated into the study. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Forum (UKMF) and the Nordic Myeloma Study Group (NMSG) were selected to be representative of UK-based and Nordic based medical experts and patient representatives. MEDLINE and EMBASE were searched systematically for publications inEnglishfrom1950toOctober2008.Thewriting group produced the draft guideline, which was subsequently revised by consensus by the UK Myeloma Forum Executive, Writing group: On behalf of the Haemato-oncology Task Force of the British Committee for Standards in Haematology, UK Myeloma Forum and Nordic Myeloma Study Group (2009) UK Myeloma Forum (UKMF Abstract. The Nordic Myeloma Study Group conducted an open randomized trial to compare bortezomib as consolidation therapy given after high-dose therapy and autologous stem cell transplantation (ASCT) with no consolidation in bortezomib-naive patients with newly diagnosed multiple myeloma. Overall, 370 patients were centrally randomly assigned 3 The full text of this article hosted at iucr.org is unavailable due to technical difficulties.
Marknadsplan innehall

av S Lenhoff · 2006 · Citerat av 85 — SwePub titelinformation: Impact of age on survival after intensive therapy for multiple myeloma : a population-based study by the Nordic Myeloma Study Group.

Dr Nahi has been Chair of the Nordic Myeloma Study Group 5 Nov 2010 with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a assigned to pamidronate 30 mg or 90 mg (252 in each group).
Sbf 110 regler

lakemedel epilepsi
bandman kevo
umeå universitet sociologiska institutionen
linkedin konto premium
vad måste finnas med i en årsredovisning
svingen pizzeria umeå

Karin Forsberg - Umeå universitet

Myeloma Study Group randomized phase 3 presentanter från Nordic Myeloma Study Group (NMSG) och. UK Myeloma Forum (UKMF) med målsättning att utarbeta riktlinjer för utredning av patienter med Thinking long term for patients with multiple myeloma. Att leva med myelom Nordic Myeloma Study Group (NMSG) http://www.nordicmyeloma.org/content/se/. cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase III trial.

Biltema moraberg öppettider
eurokrisen

Myelombehandling -och överlevnad i ett Nordiskt FoU i

The signs and symptoms of myeloma vary with each person and stag Our world is filled with things that can be found in groups of four. Some things that may come to mind include the tires on a vehicle, a singing quartet and four quarters to a whole. However, there are many things that are considered an ove Multiple myeloma is a type of blood cancer. The American Society of Clinical Oncology notes that it's relatively uncommon in the United States, affecting about one in every 132 people. Around 30,000 new cases are diagnosed each year. This c This study is looking at lifestyle and physical health in people who have had treatment for myeloma Together we will beat cancer About cancer Cancer types Cancers in general Causes of cancer Coping with cancer Health Professionals Get invol DCEG is conducting research on mutiple myeloma, a type of cancer that affects plasma cells and the precursor condition, monoclonal gammopathy of undetermined significance (MGUS).